Press-release for stocks for hcm

symbols : Hcm crawled time : 01:00

save search

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
Published: 2023-06-16 (Crawled : 01:00) - globenewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M

Health Technology

| -17.37% | O: -0.06% H: 0.53% C: -0.31%
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 38.26% | O: 3.79% H: 4.16% C: 1.53%
publication results

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Published: 2023-04-18 (Crawled : 01:00) - globenewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M

Health Technology

| -19.99% | O: 0.9% H: 0.0% C: -0.71%
LLY | News | $745.69 1.96% -0.16% 2M

Health Technology

| 98.48% | O: 0.17% H: 0.34% C: -0.83%
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 8.63% | O: 1.49% H: 2.64% C: 1.52%
china

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-12 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 17.74% | O: 5.81% H: 0.0% C: -5.37%
association cancer research meeting

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published: 2023-03-31 (Crawled : 01:00) - globenewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M

Health Technology

| -18.38% | O: 0.0% H: 0.92% C: 0.8%
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 36.19% | O: -1.19% H: 2.04% C: -1.66%
fda cancer treatment submission

HUTCHMED Confirms No Assets Held at Silicon Valley Bank
Published: 2023-03-13 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 28.52% | O: -3.38% H: 0.15% C: -1.6%

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
Published: 2022-08-08 (Crawled : 01:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M

Health Technology

| 145.27% | O: -0.22% H: 1.82% C: 0.62%
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 31.48% | O: 3.03% H: 5.21% C: -2.59%
BGNE | $139.22 6.32% 5.95% 200K

Health Technology

| -28.53% | O: 2.38% H: 3.38% C: 1.58%
global cancer study

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
Published: 2022-07-13 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| 36.19% | O: -2.31% H: 6.04% C: 2.9%
tagrisso trial presentation plus results

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Published: 2022-01-20 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -41.09% | O: -3.16% H: 3.83% C: -0.2%
hmpl-653 solid tumors trial china

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium
Published: 2022-01-19 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -41.54% | O: -0.77% H: 0.0% C: 0.0%
BGNE | $139.22 6.32% 5.95% 200K

Health Technology

| -39.97% | O: 3.04% H: 0.0% C: 0.0%
symposium gastrointestinal asco test cancer

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Published: 2021-12-06 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -44.12% | O: -7.75% H: 0.0% C: 0.0%
BGNE | $139.22 6.32% 5.95% 200K

Health Technology

| -60.4% | O: -11.5% H: 0.0% C: 0.0%
trial cancer colorectal cancer enroll

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | News | $138.73 -4.19% 3.7K

Health Technology

| 24.99% | O: -0.02% H: 1.33% C: 1.33%
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -46.23% | O: -4.39% H: 0.0% C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M

Health Technology

| 25.75% | O: -0.07% H: 0.0% C: 0.0%
orpathys lung cancer china therapy cancer trial

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting
Published: 2021-11-08 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -40.86% | O: -2.95% H: 1.04% C: 0.27%

HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture
Published: 2021-09-29 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -49.81% | O: 0.94% H: 0.79% C: -1.36%

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting
Published: 2021-09-29 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -49.81% | O: 0.94% H: 0.79% C: -1.36%
chinese presentation

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
Published: 2021-09-20 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -52.04% | O: 1.1% H: 0.0% C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M

Health Technology

| 26.13% | O: 0.0% H: 4.33% C: 4.15%
endocrine

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer
Published: 2021-08-26 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -51.82% | O: -1.66% H: 1.29% C: -0.64%
cancer breast cancer trial

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes
Published: 2021-08-23 (Crawled : 01:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K

Health Technology

| -51.26% | O: 1.36% H: 1.13% C: 0.69%